11 Weiner AL， Vieira L ， Bayer MJ. Ketamine abusers presenting to the emergency department. J Emerg Med， 2000，18(4): 447－451.

　　12 Risner ME. Intravenous self－administration of PCP and related compounds in the dog. J Pharmacol Exp Ther， 1982，221(3): 637－644.

　　13 Lahti AC， Koffel B， LaPorte D， et al. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsy_chopharmacology， 1995， 13(1): 9－19.

　　14 Trujillo KA. Effects of noncompetitive N－methyl－D－aspartate receptor antagonists on opiate tolerance and physical dependence (Review). Neuropsychopharmacology， 1995， 13(4): 301－307.

　　15 Herman BH， Vocci F， Bridge P. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. medication development issues for opiate addiction(Review). Neuropsychopharmacol_ogy， 1995， 13(4): 269－293.

　　16 Weir E. Raves: a review of the culture， the drugs and the prevention of harm. CAMJ， 2000， 162(13): 1843－1848.

　　17 Gorman EM ， Carroll RT. Substance abuse and HIV. J Assoc Nurses AIDS Care， 2000， 11(2): 51－62.